Transfer of malignant trait to BRCA1 deficient human fibroblasts following exposure to serum of cancer patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-9966
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Transfer of malignant trait to BRCA1 deficient human fibroblasts following exposure to serum of cancer patients ; volume:35 ; number:1 ; day:14 ; month:5 ; year:2016 ; pages:1-12 ; date:12.2016
Journal of experimental & clinical cancer research ; 35, Heft 1 (14.5.2016), 1-12, 12.2016
- Urheber
-
Hamam, Dana
- Beteiligte Personen und Organisationen
-
Abdouh, Mohamed
Gao, Zu-Hua
Arena, Vincenzo
Arena, Manuel
Arena, Goffredo Orazio
SpringerLink (Online service)
- DOI
-
10.1186/s13046-016-0360-9
- URN
-
urn:nbn:de:1111-2016051828620
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hamam, Dana
- Abdouh, Mohamed
- Gao, Zu-Hua
- Arena, Vincenzo
- Arena, Manuel
- Arena, Goffredo Orazio
- SpringerLink (Online service)
Ähnliche Objekte (12)
Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells
BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy
Dysregulated proteome and N‐glycoproteome in ALG1‐deficient fibroblasts
PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors
Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression
Sil1-deficient fibroblasts generate an aberrant extracellular matrix leading to tendon disorganisation in Marinesco-Sjögren syndrome
How to reprogram human fibroblasts to neurons
Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells
BRCA1 deficient mammary tumors are dependent on EZH2 expression and sensitive to polycomp repressive complex 2-inhibitor 3-deazaneplanocin A
FANCJ promotes PARP1 activity during DNA replication that is essential in BRCA1 deficient cells
Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer
Anti‐tumoural activity of the G‐quadruplex ligand pyridostatin against BRCA1/2‐deficient tumours
Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells
BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy
Dysregulated proteome and N‐glycoproteome in ALG1‐deficient fibroblasts
PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors
Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression
Sil1-deficient fibroblasts generate an aberrant extracellular matrix leading to tendon disorganisation in Marinesco-Sjögren syndrome
How to reprogram human fibroblasts to neurons
Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells
BRCA1 deficient mammary tumors are dependent on EZH2 expression and sensitive to polycomp repressive complex 2-inhibitor 3-deazaneplanocin A
FANCJ promotes PARP1 activity during DNA replication that is essential in BRCA1 deficient cells
Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer
Anti‐tumoural activity of the G‐quadruplex ligand pyridostatin against BRCA1/2‐deficient tumours
Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells
BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy
Dysregulated proteome and N‐glycoproteome in ALG1‐deficient fibroblasts
PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors
Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression
Sil1-deficient fibroblasts generate an aberrant extracellular matrix leading to tendon disorganisation in Marinesco-Sjögren syndrome
How to reprogram human fibroblasts to neurons
Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells
BRCA1 deficient mammary tumors are dependent on EZH2 expression and sensitive to polycomp repressive complex 2-inhibitor 3-deazaneplanocin A
FANCJ promotes PARP1 activity during DNA replication that is essential in BRCA1 deficient cells
Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer